Skip to main content
. 2016 Feb;23(6):520–577. doi: 10.2174/0929867323666151223095839

Table 14. Sterling in vivo antitumor data for analog 110 (WIN-58161).

Tumor Drug route/schedule Max. tolerated total dosea (mg/kg) %T/Cb %ILSc
Panc03 s.c., qd 3-9 781 17
Colo38 s.c., qd 3-9 504 0
Mam16C s.c., qd 1-4 263 15
B16 i.p., qd 1,5,9 1500 66
P388 i.p., qd 1,5,9 1014 90

aMaximum non-lethal dose; btumor growth inhibition where T and C are median tumor weights of the treatment and control groups respectively; cpercent increased life span.